| Drug Name |
Prazosin |
| Drug ID |
BADD_D01827 |
| Description |
Prazosin, also known as _Minipress_, is a drug used to treat hypertension. Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988 [L5828]. It belongs to the class of drugs known as alpha-1 antagonists [FDA label], [A176630].
Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTSD) and associated nightmares [A176618, A176621, A176624]. |
| Indications and Usage |
For treatment of hypertension, symptomatic benign prostatic hyperplasia, and severe congestive heart failure. May also be used alone or in combination with β-blockers in the preoperative management of signs and symptoms of pheochromocytoma. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
C02CA01 |
| DrugBank ID |
DB00457
|
| KEGG ID |
D08411
|
| MeSH ID |
D011224
|
| PubChem ID |
4893
|
| TTD Drug ID |
D0WV3U
|
| NDC Product Code |
Not Available |
| Synonyms |
Prazosin | Furazosin | Prazosin Hydrochloride | Hydrochloride, Prazosin | Prazosin HCL | HCL, Prazosin | Minipress | Pratsiol |
